Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:03 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 7,083 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer Clear all
Terminated Phase 2 Interventional Results available

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

NCT05954143
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2-positive Breast Cancer
Interventions
BDC-1001, Pertuzumab
Drug
Lead sponsor
Bolt Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Irvine, California • New York, New York • Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Nov 3, 2026, 6:03 PM EST
Completed Phase 1Phase 2 Interventional Results available

Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer

NCT02018458
View directory record Official record
Conditions
Breast Cancer
Interventions
LA TNBC: DC vaccine+Preop chemo, ER+/HER2-BC:DC vaccine+Preop chemo
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Nov 3, 2026, 6:03 PM EST
Not listed No phase listed Observational

Assessing Breast Density's Value in Imaging - A Comparative Effectiveness Study

NCT02980848
View directory record Official record
Conditions
Breast Cancer
Interventions
Screening digital mammography, Screening digital breast tomosynthesis, Screening breast magnetic resonance imaging, Diagnostic mammography, Pre-operative breast magnetic resonance imaging
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
1,341,172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Davis, California • San Francisco, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Nov 3, 2026, 6:03 PM EST
Completed No phase listed Observational

Novel Molecular Targets for Ductal Carcinoma In Situ (DCIS)

NCT03148015
View directory record Official record
Conditions
Breast Cancer
Interventions
Biomarkers
Other
Lead sponsor
Sentara Norfolk General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Newport News, Virginia
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Nov 3, 2026, 6:03 PM EST
Terminated Phase 2 Interventional Results available

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

NCT01151215
View directory record Official record
Conditions
Neoplasms, Breast Neoplasms, Breast Cancer
Interventions
AZD8931, anastrozole, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Nov 3, 2026, 6:03 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

NCT05198843
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Inflammatory Carcinoma
Interventions
Dasatinib, Icosapent Ethyl
Drug · Dietary Supplement
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Nov 3, 2026, 6:03 PM EST
Not listed Phase 2 Interventional

Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer

NCT00499525
View directory record Official record
Conditions
Breast Cancer
Interventions
paclitaxel, sorafenib tosylate, placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
43
States / cities
Muscle Shoals, Alabama • Fayetteville, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Nov 3, 2026, 6:03 PM EST
Active, not recruiting Not applicable Interventional

Excision Followed by Radiofrequency Ablation for Breast Cancer

NCT01153035
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiofrequency Ablation
Device
Lead sponsor
University of Arkansas
Other
Eligibility
50 Years to 100 Years · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
6
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Nov 3, 2026, 6:03 PM EST
Completed Phase 1 Interventional

Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors

NCT02257476
View directory record Official record
Conditions
Neoplasms, Malignancies
Interventions
Carfilzomib, Dexamethasone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Nov 3, 2026, 6:03 PM EST
Completed Not applicable Interventional

Study of Barriers to Beginning and Finishing Treatment for Patients With Breast Cancer

NCT00937989
View directory record Official record
Conditions
Breast Cancer
Interventions
educational intervention, informational intervention, medical chart review, questionnaire administration, study of socioeconomic and demographic variables, quality-of-life assessment
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
50 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Nov 3, 2026, 6:03 PM EST
Completed Phase 1 Interventional

A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

NCT02627274
View directory record Official record
Conditions
Solid Tumor, Breast Cancer, Cancer of Head and Neck
Interventions
RO6874281, Trastuzumab, Cetuximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
5
States / cities
Tucson, Arizona • La Jolla, California • Greeley, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Nov 3, 2026, 6:03 PM EST
Completed Not applicable Interventional

Testing Health-Related Interventions: Voices of Equity Needed to Overcome Weight-bias in Obesity-Cancer Care

NCT07897890
View directory record Official record
Conditions
Obesity & Overweight, Breast Cancer
Interventions
THRIVE NOW
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 3, 2026, 6:03 PM EST
Recruiting Not applicable Interventional

Cryoablation vs Lumpectomy in T1 Breast Cancers

NCT05505643
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm
Interventions
Endocare SlimLine Cryoprobe, Lumpectomy
Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 3, 2026, 6:03 PM EST
Not listed Not applicable Interventional

Exercise Program or Health Education Program in Reducing Fatigue and Pain in Breast Cancer Survivors

NCT00336089
View directory record Official record
Conditions
Breast Cancer, Cancer Survivor, Fatigue, Pain
Interventions
exercise intervention, educational intervention, complementary or alternative medicine procedure, fatigue assessment and management, management of therapy complications, pain therapy, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
Clayton State University
Other
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Atlanta, Georgia • Morrow, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Nov 3, 2026, 6:03 PM EST
Active, not recruiting Not applicable Interventional

Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial

NCT06216574
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Internet-based Intervention
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
236
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Antioch, California + 199 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Nov 3, 2026, 6:03 PM EST
Completed Phase 2 Interventional Results available

Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer

NCT00290758
View directory record Official record
Conditions
Breast Cancer
Interventions
placebo, genistein, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Nov 3, 2026, 6:03 PM EST
Active, not recruiting Phase 2 Interventional

Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

NCT05637216
View directory record Official record
Conditions
Radiation Induced Fibrosis
Interventions
Losartan 25 milligram capsule, Placebo
Drug
Lead sponsor
Shaw Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Edwards, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Nov 3, 2026, 6:03 PM EST
Recruiting Phase 1 Interventional

A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

NCT06246968
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Cancer, Breast Cancer Stage IV, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Metastatic Triple-Negative Breast Carcinoma, Locally Advanced Breast Cancer, Locally Advanced Triple-Negative Breast Carcinoma
Interventions
Pembrolizumab, Cryoablation, Histotripsy
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 3, 2026, 6:03 PM EST
Completed Not applicable Interventional

Sexual Health and Breast Cancer: Developing Appropriate Education for Women Going Through Treatment

NCT06121258
View directory record Official record
Conditions
Breast Cancer Female, Sexual Dysfunction
Interventions
Educational video series
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 3, 2026, 6:03 PM EST
Completed No phase listed Observational

Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer

NCT00283608
View directory record Official record
Conditions
Breast Cancer
Interventions
Single nucleotide polymorphism (SNP), high performance liquid chromatography, measurements by DXA, questionnaire administration
Genetic · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2011 · Synced Nov 3, 2026, 6:03 PM EST
Not listed Phase 2 Interventional

Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue

NCT00651417
View directory record Official record
Conditions
Localized Breast Cancer, Localized Prostate Cancer, Patients Receiving External Beam Radiotherapy
Interventions
Organic Germanium, Placebo
Dietary Supplement
Lead sponsor
Arizona Oncology Services
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Nov 3, 2026, 6:03 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions

NCT01331447
View directory record Official record
Conditions
Breast Cancer
Interventions
exemestane
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Nov 3, 2026, 6:03 PM EST
Completed Phase 2 Interventional Results available

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

NCT02401347
View directory record Official record
Conditions
Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer
Interventions
Talazoparib Tosylate
Drug
Lead sponsor
Melinda Telli
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Nov 3, 2026, 6:03 PM EST
Recruiting Phase 1Phase 2 Interventional

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

NCT03449238
View directory record Official record
Conditions
Metastatic Breast Cancer, Brain Metastases
Interventions
Pembrolizumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years to 90 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 3, 2026, 6:03 PM EST